Imdevimab Terminated Phase 3 Trials for Coronavirus Disease 2019 (COVID‑19) Treatment

IndicationsStatusPurposePhase
TerminatedTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT04425629Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19
NCT05205759Non-inferiority Trial on Monoclonal Antibodies in COVID-19